Abstract
The role of 18FDG-PET/CT during follow-up of patients affected by Hodgkin’s lymphoma (HL) in complete remission after treatment is not fully elucidated, since a wide use of 18F fluorodeoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT) in this setting could be limited by a relative high rate of false-positive results. Herein, we summarize a retrospective analysis of 27 patients with Hodgkin’s lymphoma in complete remission after the first-line (n = 20) or salvage (n = 7) therapy receiving serial 18FDG-PET/CT scans during follow-up. Out of 165 scans, 13 were suspected for relapse, which was confirmed in seven patients. All relapses were correctly identified by 18FDG-PET/CT positivity, with a 100% sensitivity; false-positive rate was 46% and negative predictive value was 100%. True-positive findings were mostly associated with multiple sites, subdiaphragmatic involvement, and/or previous sites of disease. According to our results, we conclude that performing routine PET/CT scan during follow-up of those patients who are at high risk of relapse would be advisable, although caution must be adopted when interpreting PET/CT results due to the relatively high rate of false-positive findings. If FDG abnormal uptake is present at multiple nodal sites, subdiaphragmatic lymph nodes, or previous sites of disease, histological verification of PET abnormal findings is warranted.
Similar content being viewed by others
References
Zinzani PL, Tani M, Trisolini R et al (2007) Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. Haematologica 92:771–777. doi:10.3324/haematol.10798
Isasi CR, Lu P, Blaufox MD (2005) A meta-analysis of 18F-2-deoxy-2-fluoro-d-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 104:1066–1074. doi:10.1002/cncr.21253
Rigacci L, Vitolo U, Nassi L et al (2007) Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol 86:897–903. doi:10.1007/s00277-007-0356-9
Schaefer NG, Strobel K, Taverna C et al (2007) Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med 34:60–67. doi:10.1007/s00259-006-0238-8
Hernandez-Maraver D, Hernandez-Navarro F, Gomez-Leon N et al (2006) Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma. Br J Haematol 135:293–302. doi:10.1111/j.1365-2141.2006.06284.x
Gallamini A, Hutchings M, Rigacci L et al (2007) Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian–Danish study. J Clin Oncol 25:3746–3752. doi:10.1200/JCO.2007.11.6525
Hutchings M, Loft A, Hansen M et al (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52–59. doi:10.1182/blood-2005-06-2252
Haioun C, Itti E, Rahmouni E et al (2005) [18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106:1376–1381. doi:10.1182/blood-2005-01-0272
Querellou S, Valette F, Bodet-Milin C et al (2006) FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin’s lymphoma and Hodgkin’s disease. Ann Hematol 85:759–767. doi:10.1007/s00277-006-0151-z
Schot BW, Zijlstra JM, Sluiter WJ et al (2007) Early FDG-PET assessment in combination with clinical risk scores determines prognosis in relapsed lymphoma. Blood 109:486–491. doi:10.1182/blood-2005-11-006957
Spaepen K, Stroobants S, Dupont P et al (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414–419
Spaepen K, Stroobants S, Dupont P et al (2001) Can positron emission tomography with [(18) F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 115:272–278. doi:10.1046/j.1365-2141.2001.03169.x
Weihrauch MR, Re D, Scheidhauer K et al (2001) Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 98:2930–2934. doi:10.1182/blood.V98.10.2930
Juweid ME, Stroobants S, Hoekstra O et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of International Harmonization Project in lymphoma. J Clin Oncol 25:571–578. doi:10.1200/JCO.2006.08.2305
Kobe C, Dietlein M, Franklin J et al (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112:3989–3994. doi:10.1182/blood-2008-06-155820
Hutchings M, Loft A, Hansen M et al (2007) Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol 78:206–212. doi:10.1111/j.1600-0609.2006.00802.x
Jerusalem G, Beguin Y, Fassotte MF et al (2003) Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease. Ann Oncol 14:123–130. doi:10.1093/annonc/mdg011
Schaefer HG, Taverna C, Strobel K et al (2007) Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy - is biopsy of FDG-avid lesions still needed? Radiology 244:257–262. doi:10.1148/radiol.2441060810
Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586. doi:10.1200/JCO.2006.09.2403
Crocchiolo R, Canevari C, Assanelli A et al (2008) Pre-transplant FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. Leuk Lymphoma 49:727–733. doi:10.1080/10428190701885545
Cremerius U, Fabry U, Wildberger JE et al (2002) Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin’s lymphoma. Bone Marrow Transplant 30:103–111. doi:10.1038/sj.bmt.1703607
Schot BW, Pruim J, van Imhoff GW et al (2006) The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma. Haematologica 91:490–495
Filmont JE, Czernin J, Yap C et al (2003) Value of F-18-fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest 124:608–613. doi:10.1378/chest.124.2.608
Svoboda J, Andreadis C, Elstrom R et al (2006) Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 38:211–216. doi:10.1038/sj.bmt.1705416
Derenzini E, Musuraca G, Fanti S et al (2008) Pre-transplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer 113:2496–2503. doi:10.1002/cncr.23861
Dodero A, Crocchiolo R, Patriarca F et al (2007) Prognostic value of positron emission tomography (PET) scan in patients with relapsed Hodgkin lymphoma or aggressive non-Hodgkin lymphoma receiving salvage chemotherapy followed by reduced-intensity allogeneic stem cell transplantation. Blood Abs#3039
Torrey MJ, Poen JC, Hoppe RT (1997) Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies. J Clin Oncol 15:1123–1130
Radford JA, Eardley A, Woodman C et al (1997) Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. BMJ 314:343–346
Baron F, Storb R, Storer BE et al (2006) Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 24:4150–4157. doi:10.1200/JCO.2006.06.9914
Corradini P, Dodero A, Farina L et al (2007) Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 22:2316–2323. doi:10.1038/sj.leu.2404822
Freytes CO, Loberiza FR, Rizzo JD et al (2004) Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 104:3797–3803. doi:10.1182/blood-2004-01-0231
Levine JM, Weiner M, Kelly KM (2006) Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate. J Pediatr Hematol Oncol 28:711–714. doi:10.1097/01.mph.0000243648.66734.eb
Meany HJ, Gidvani VK, Minniti CP (2007) Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer 48:399–402. doi:10.1002/pbc.20797
Zinzani PL, Stefoni V, Tani M et al (2009) Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 27:1781–1787
Sonet A, Graux C, Nollevaux NC et al (2007) Unsuspected FDG-PET findings in the follow-up of patients with lymphoma. Ann Hematol 86:9–15. doi:10.1007/s00277-006-0167-4
Acknowledgments
We are grateful to all doctors and nurses involved in the care of patients of the Hematology and BMT Unit and Nuclear Medicine Division.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Crocchiolo, R., Fallanca, F., Giovacchini, G. et al. Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin’s lymphoma. Ann Hematol 88, 1229–1236 (2009). https://doi.org/10.1007/s00277-009-0752-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-009-0752-4